Side-Effect Management

Laboratory Markers Found to Correlate With Symptom Burden in Relapsed/Refractory Multiple Myeloma

By

Vicki Moore, PhD

Study finds correlation between certain laboratory markers and symptom burden in patients with relapsed/refractory multiple myeloma.

Chronic Immune-Mediated Diarrhea and Colitis Associated With Prolonged Survival in Patients Treated With ICIs

By

Susan Moench, PhD, PA-C

The immune-related AE, immune-mediated diarrhea and colitis, can have a limited course or may exist for long-term periods.

Electronic Patient-Reported Outcomes Symptom Monitoring System Receives Mixed Reviews From Nurses

By

Bette Weinstein Kaplan

Investigators sought to determine the efficacy of using electronic PRO systems to monitor and manage symptoms in patients with advanced and metastatic cancer.

Prevalence of Insomnia Syndrome Found to Be High in Patients With Cancer

By

Susan Moench, PhD, PA-C

Using a self-report questionnaire, investigators sought to distinct insomnia syndrome distinct from sleep disturbance in patients with cancer.

Addition to Supportive Care Documentation Decreased AE Risks Associated With High-Dose Methotrexate

By

Susan Moench, PhD, PA-C

Incorporating 2 standardized documents into the process for supportive care measures improved outcomes for patients receiving HD-MTX.

Distinguishing Neutropenia From Pseudoneutropenia Can Preserve Antineoplastic Therapy

By

Susan Moench, PhD, PA-C

Retrospective analysis demonstrates the value in distinguishing between these conditions to salvage chemotherapy and/or targeted therapy dose in patients with cancer.

Direct Oral Anticoagulants as Effective as Vitamin K Antagonists for Thromboembolic Events With Myeloproliferative Neoplasms

By

Vicki Moore, PhD

The efficacy and safety of direct oral anticoagulants and vitamin K antagonists in the treatment of ATEs/VTEs in patients with MPNs was compared.

Treatment-Related Toxicities and Overnight Fasting Before Lapatinib Administration

By

Vicki Moore, PhD

Researchers compared adverse effect incidence with lapatinib administration at 3 different times of the day.

Risk for SARS-CoV-2 Infection Lower for O, Rh− Blood Groups

Risk for severe COVID-19 illness or death is lower for O versus all other groups, for Rh− versus Rh+.

HIGH-2-LOW Risk Assessment Tool Stratifies Patient Risk for Venous Thromboembolism

By

Jessica Nye, PhD

This newly developed tool used several measures to successfully stratify risk of VTE in patients with hematologic cancers.